COMBO: An AmpliSeq-based trilogy for autosomal and uniparental (Y & mito) biogeographical ancestry and appearance testing.

Forensic Sci Int Genet

Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria; Population Genetics and Evolution, i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. Electronic address:

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Forensic DNA phenotyping has become an increasingly important technology for narrowing down potential stain donors in forensic investigations. Over the past decade, the number of genetic markers required for reliable predictions has steadily increased, posing significant challenges for molecular genetic assay designs. These parallel designs often consume valuable DNA extracted from forensically relevant materials. To minimize DNA wastage, it is crucial to integrate as many markers as possible into a single analytical approach. Massively Parallel Sequencing (MPS)-based technologies have enabled the simultaneous analysis of up to several hundred genetic markers in one reaction. However, to date, marker panels from nuclear and mitochondrial DNA have not been integrated. This limitation has led to increased consumption of evidentiary DNA, as parallel analytical schemes are required to analyze both types of markers. This study presents the development, optimization and validation of the COMBO Panel, which combines autosomal and uniparental (Y-chromosomal and mitochondrial DNA) markers for ancestry and appearance testing. The COMBO panel contains 524 (VISAGE Enhanced Tool, ET) or 153 (VISAGE Basic Tool, BT) markers for the prediction of appearance and ancestry with 781 Y-chromosomal SNPs and 162 mtDNA amplicons covering the entire mitogenome. Library generation is based on AmpliSeq technology, which allows simultaneous analysis of all markers in a single sequencing run. The VISAGE ET panel was used in the optimization phase as well as in the initial trials of the COMBO assay and was later replaced with the VISAGE BT panel to streamline the test and adjust the primer concentrations accordingly. The COMBO panel was analyzed using Ion GeneStudio S5 systems for testing sensitivity and reproducibility, sex and species specificity, mock and real casework, degraded DNA and historical samples.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fsigen.2025.103349DOI Listing

Publication Analysis

Top Keywords

combo panel
12
autosomal uniparental
8
ancestry appearance
8
appearance testing
8
genetic markers
8
markers single
8
simultaneous analysis
8
mitochondrial dna
8
visage panel
8
dna
7

Similar Publications

COMBO: An AmpliSeq-based trilogy for autosomal and uniparental (Y & mito) biogeographical ancestry and appearance testing.

Forensic Sci Int Genet

August 2025

Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria; Population Genetics and Evolution, i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. Electronic address:

Forensic DNA phenotyping has become an increasingly important technology for narrowing down potential stain donors in forensic investigations. Over the past decade, the number of genetic markers required for reliable predictions has steadily increased, posing significant challenges for molecular genetic assay designs. These parallel designs often consume valuable DNA extracted from forensically relevant materials.

View Article and Find Full Text PDF

Analytical and Clinical Validation of the ConfiSign HIV Self-Test for Blood-Based HIV Screening.

Diagnostics (Basel)

July 2025

Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

: Since the World Health Organization (WHO) recommended HIV self-testing as an alternative to traditional facility-based testing in 2016, it has been increasingly adopted worldwide. This study aimed to evaluate the performance of the ConfiSign HIV Self-Test (GenBody Inc., Republic of Korea), a newly developed blood-based immunochromatographic assay for the qualitative detection of total antibodies (IgG and IgM) against HIV-1/HIV-2.

View Article and Find Full Text PDF

Background: Adolescents living with HIV are vulnerable to hepatitis B coinfection. However, the prevalence of hepatitis B virus (HBV) exposure and the persistence of childhood vaccine-induced HBV antibodies in this population remain unclear. This study assessed HBV exposure and the prevalence of protective Hepatitis B Surface Antibody (HBsAb) levels among adolescents living with HIV referred for viral load testing at the national reference laboratory in Uganda.

View Article and Find Full Text PDF

Background: While electronic cigarettes (ECIG) may have lower toxicant delivery than cigarettes, ECIG-liquids and aerosols still contain toxicants that can potentially disrupt lung lipid homeostasis.

Methods: Participants from two studies underwent bronchoscopy and bronchoalveolar lavage (BAL). Ninety-eight participants (21-44 years old) were included in a cross-sectional study, with 17 ECIG users, 52 non-smokers, and 29 smokers.

View Article and Find Full Text PDF

Objectives: The goal of this study is to evaluate the analytical and clinical performance of a new human immunodeficiency virus antigen and antibody (HIV Ag/Ab) test using light-initiated chemiluminescent assay (LiCA) and compare it with the well-established Architect HIV Ag/Ab combo assay in a clinical setting.

Methods: We used banked samples and national reference controls to identify the ability to detect HIV Ag/Ab and different viral subtypes. Thirteen seroconversion panels were tested to evaluate early detection of HIV.

View Article and Find Full Text PDF